172 related articles for article (PubMed ID: 31628561)
1. Variation in receipt of therapy and survival with provider volume for medical oncology in non-curative esophago-gastric cancer: a population-based analysis.
Hallet J; Davis LE; Mahar AL; Liu Y; Zuk V; Gupta V; Earle CC; Coburn NG
Gastric Cancer; 2020 Mar; 23(2):300-309. PubMed ID: 31628561
[TBL] [Abstract][Full Text] [Related]
2. Benefits of High-Volume Medical Oncology Care for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis.
Hallet J; Davis L; Mahar A; Mavros M; Beyfuss K; Liu Y; Law CHL; Earle C; Coburn N
J Natl Compr Canc Netw; 2020 Mar; 18(3):297-303. PubMed ID: 32135510
[TBL] [Abstract][Full Text] [Related]
3. Economic impacts of care by high-volume providers for non-curative esophagogastric cancer: a population-based analysis.
Hallet J; Look Hong NJ; Zuk V; Davis LE; Gupta V; Earle CC; Mittmann N; Coburn NG
Gastric Cancer; 2020 May; 23(3):373-381. PubMed ID: 31834527
[TBL] [Abstract][Full Text] [Related]
4. Association Between Treatment at High-Volume Facilities and Improved Overall Survival in Soft Tissue Sarcomas.
Venigalla S; Nead KT; Sebro R; Guttmann DM; Sharma S; Simone CB; Levin WP; Wilson RJ; Weber KL; Shabason JE
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):1004-1015. PubMed ID: 29485042
[TBL] [Abstract][Full Text] [Related]
5. Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma.
Huntington SF; Hoag JR; Zhu W; Wang R; Zeidan AM; Giri S; Podoltsev NA; Gore SD; Ma X; Gross CP; Davidoff AJ
Cancer; 2018 Nov; 124(21):4211-4220. PubMed ID: 30216436
[TBL] [Abstract][Full Text] [Related]
6. Geographic impact on access to care and survival for non-curative esophagogastric cancer: a population-based study.
Yee EK; Coburn NG; Zuk V; Davis LE; Mahar AL; Liu Y; Gupta V; Darling G; Hallet J
Gastric Cancer; 2021 Jul; 24(4):790-799. PubMed ID: 33550518
[TBL] [Abstract][Full Text] [Related]
7. Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer.
Sylvie L; Silvia S; Salah-Eddin AB; Markus F; Florian L; Peter TP; Bernhard H; Martin A; Alexander N
Eur J Cancer; 2015 Sep; 51(14):1918-26. PubMed ID: 26216588
[TBL] [Abstract][Full Text] [Related]
8. Survival of esophageal and gastric cancer patients with adjuvant and palliative chemotherapy-a retrospective analysis of a register-based patient cohort.
Ekheden I; Ebrahim F; Ólafsdóttir H; Raaschou P; Wettermark B; Henriksson R; Ye W
Eur J Clin Pharmacol; 2020 Jul; 76(7):1029-1041. PubMed ID: 32372150
[TBL] [Abstract][Full Text] [Related]
9. Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer.
Aviki EM; Lavery JA; Roche KL; Cowan R; Dessources K; Basaran D; Green AK; Aghajanian CA; O'Cearbhaill R; Jewell EL; Leitao MM; Gardner GJ; Abu-Rustum NR; Sabbatini P; Bach PB
Gynecol Oncol; 2020 Nov; 159(2):418-425. PubMed ID: 32814642
[TBL] [Abstract][Full Text] [Related]
10. Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study.
Dijksterhuis WPM; Verhoeven RHA; Pape M; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; Lemmens VEPP; van Oijen MGH; van Laarhoven HWM
Eur J Cancer; 2020 Nov; 139():107-118. PubMed ID: 32980749
[TBL] [Abstract][Full Text] [Related]
11. Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03).
Athauda A; Nankivell M; Langley RE; Alderson D; Allum W; Grabsch HI; Starling N; Chau I; Cunningham D
Eur J Cancer; 2020 Sep; 137():45-56. PubMed ID: 32745964
[TBL] [Abstract][Full Text] [Related]
12. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices.
Paulson AS; Hess LM; Liepa AM; Cui ZL; Aguilar KM; Clark J; Schelman W
Gastric Cancer; 2018 Sep; 21(5):831-844. PubMed ID: 29397460
[TBL] [Abstract][Full Text] [Related]
13. Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer.
Vasista A; Stockler M; Martin A; Pavlakis N; Sjoquist K; Goldstein D; Gill S; Jain V; Liu G; Kannourakis G; Kim YH; Nott L; Snow S; Burge M; Harris D; Jonker D; Chua YJ; Epstein R; Bonaventura A; Kiely B
Oncologist; 2019 Nov; 24(11):e1102-e1107. PubMed ID: 30936377
[TBL] [Abstract][Full Text] [Related]
14. A retrospective cohort study of patients with stomach and liver cancers: the impact of comorbidity and ethnicity on cancer care and outcomes.
Sarfati D; Gurney J; Stanley J; Koea J
BMC Cancer; 2014 Nov; 14():821. PubMed ID: 25380581
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study.
Dijksterhuis WPM; Verhoeven RHA; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
Int J Cancer; 2020 Apr; 146(7):1889-1901. PubMed ID: 31340065
[TBL] [Abstract][Full Text] [Related]
17. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
18. Gastrectomy case volume and textbook outcome: an analysis of the Population Registry of Esophageal and Stomach Tumours of Ontario (PRESTO).
Levy J; Gupta V; Amirazodi E; Allen-Ayodabo C; Jivraj N; Jeong Y; Davis LE; Mahar AL; De Mestral C; Saarela O; Coburn N;
Gastric Cancer; 2020 May; 23(3):391-402. PubMed ID: 31686260
[TBL] [Abstract][Full Text] [Related]
19. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Sudarshan M; Alcindor T; Ades S; Aloraini A; van Huyse M; Asselah J; David M; Frechette D; Brisson S; Thirlwell M; Ferri L
Ann Surg Oncol; 2015 Jan; 22(1):324-30. PubMed ID: 25023544
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Academic Facility Type and Case Volume on Survival in Patients Undergoing Curative Radiation Therapy for Muscle-Invasive Bladder Cancer.
Bajaj A; Martin B; Bhasin R; Hentz C; Block AM; Harkenrider MM; Solanki AA
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):851-857. PubMed ID: 29485062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
